Circulating Thrombotic Risk Factors in Young Patients with Coronary Artery Disease Who Are on Statins and

Reema George1, Harikrishnan Sivadasanpillai1, Narayani Jayakumari2

  • 1Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, 695011 Kerala India.

Insights

This study found that low antithrombin-III, high fibrinogen, and high lipoprotein(a) are key thrombotic risk factors for premature coronary artery disease (CAD) in Indian patients. Managing these alongside conventional factors may aid CAD prevention.

Area of Science:

  • Cardiovascular Medicine
  • Thrombosis and Hemostasis
  • Preventive Cardiology

Background:

  • Premature coronary artery disease (CAD) is influenced by thrombotic factors beyond conventional risks.
  • Limited data exists on thrombotic factors in young Indian patients with premature CAD.
  • This study investigates thrombotic and atherogenic factors in young Indian CAD patients on statins and anti-platelet therapy.

Purpose of the Study:

  • To evaluate the role of thrombotic and atherogenic factors in young, angiographically proven CAD patients.
  • To assess these factors in Indian patients undergoing treatment with statins and anti-platelet drugs.

Main Methods:

  • A case-control study involving 152 patients (≤55 years) with CAD and 102 asymptomatic controls.
  • Analysis of clinical and biochemical data, including blood levels of fibrinogen, antithrombin-III, t-PA, PAI-1, v-WF, Lp(a), and homocysteine.
  • Logistic regression analysis to identify independent risk factors.

Main Results:

  • Patients exhibited higher conventional CAD risk factors (diabetes, smoking, hypertension, dyslipidemia, family history).
  • Independent risk factors identified: low antithrombin-III (OR 11.2), high fibrinogen (OR 6.04), and high Lp(a) (OR 4.54).
  • Plasminogen activator inhibitor-1 (PAI-1) levels were significantly lower in patients (OR 0.15); t-PA, v-WF, and homocysteine showed no significant difference.

Conclusions:

  • Low antithrombin-III, high fibrinogen, and high Lp(a) are significant independent risk factors for premature CAD in this Indian cohort.
  • Current treatments (statins, anti-platelets) may influence some thrombotic factor levels.
  • Targeting thrombotic factors alongside conventional risk factors is recommended for primary and secondary CAD prevention.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
567
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
373
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
455